Seizert Capital Partners LLC Acquires 11,224 Shares of Prestige Consumer Healthcare Inc. $PBH

Seizert Capital Partners LLC increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 19.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,620 shares of the company’s stock after acquiring an additional 11,224 shares during the period. Seizert Capital Partners LLC owned approximately 0.14% of Prestige Consumer Healthcare worth $4,282,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. UMB Bank n.a. boosted its holdings in shares of Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares during the period. Bank of Montreal Can lifted its position in Prestige Consumer Healthcare by 2.0% in the second quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock worth $747,000 after buying an additional 182 shares during the last quarter. Cerity Partners LLC boosted its stake in Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after buying an additional 218 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after acquiring an additional 250 shares during the last quarter. Finally, F m Investments LLC raised its stake in shares of Prestige Consumer Healthcare by 0.5% in the second quarter. F m Investments LLC now owns 53,369 shares of the company’s stock valued at $4,262,000 after acquiring an additional 259 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $65.07 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $90.04. The company has a market capitalization of $3.13 billion, a PE ratio of 16.15, a P/E/G ratio of 2.04 and a beta of 0.40. The company has a 50 day moving average price of $61.51 and a 200-day moving average price of $65.02.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The business had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The business’s revenue was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.09 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the sale, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on PBH. Jefferies Financial Group dropped their price target on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Canaccord Genuity Group reduced their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target for the company in a research note on Wednesday, September 24th. Finally, Oppenheimer cut their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $85.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).